Home › NDC Lookup › RxCUI directory › RxCUI 349472

Gefitinib 250 MG Oral Tablet — RxCUI 349472

Name: Gefitinib 250 MG Oral Tablet (RxCUI 349472)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 349472 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI349472

Official nameGefitinib 250 MG Oral Tablet

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped5

Package NDCs mapped7

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Gefitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Gefitinib only works in lung cancers that carry specific EGFR gene mutations — specifically an exon 19 deletion or an exon 21 (L858R) mutation. Without those mutations, the drug ha...
Why do I need a genetic test before starting gefitinib?
Good news — you can take gefitinib with or without food, whichever works best for your routine. There are no specific foods listed as a concern, but some medicines that affect your...
Can I take gefitinib with food, and are there any foods or drinks I should avoid?

📖 Read our full Gefitinib guide →

🕸️ Concept Web — How Gefitinib 250 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Gefitinib 250 MG Oral Tablet RxCUI 349472 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Gefitinib 328134 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Iressa 281883 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Gefitinib Oral Tablet 378629 SCDF
- Gefitinib Oral Product 1156708 SCDG
- Gefitinib Pill 1156709 SCDG
- Gefitinib Oral Tablet [Iressa] 402435 SBDF
- Iressa Oral Product 1176762 SBDG
- Iressa Pill 1176763 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Gefitinib 250 MG 358777 SCDC
- Gefitinib 250 MG Oral Tablet [Iressa] 402091 SBD
- Gefitinib 250 MG [Iressa] 576099 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Gefitinib 250 MG SCDC · 358777
Gefitinib Oral Tablet SCDF · 378629
Gefitinib Oral Product SCDG · 1156708
Gefitinib Pill SCDG · 1156709

Brand-Name Concepts

Gefitinib 250 MG Oral Tablet [Iressa] SBD · 402091
Gefitinib 250 MG [Iressa] SBDC · 576099
Gefitinib Oral Tablet [Iressa] SBDF · 402435
Iressa Oral Product SBDG · 1176762
Iressa Pill SBDG · 1176763
Iressa BN · 281883

📦 FDA Products & Package NDCs

5 products · 7 package NDCs

7 package NDCs map to RxCUI 349472 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00310-0482-30	30 TABLET, COATED in 1 BOTTLE (0310-0482-30)	IRESSA	AstraZeneca Pharmaceuticals LP	2015-07-13
00480-4053-56	30 TABLET, FILM COATED in 1 BOTTLE (0480-4053-56)	Gefitinib	Teva Pharmaceuticals, Inc.	2023-06-21
50742-0366-30	30 TABLET, COATED in 1 BOTTLE (50742-366-30)	Gefitinib	Ingenus Pharmaceuticals, LLC	2023-04-27
67184-0531-01	30 TABLET, COATED in 1 BOTTLE (67184-0531-1)	Gefitinib	Qilu Pharmaceutical Co., Ltd.	2023-02-13
67184-0531-02	500 TABLET, COATED in 1 BOTTLE (67184-0531-2)	Gefitinib	Qilu Pharmaceutical Co., Ltd.	2023-02-13
67184-0531-03	3 BLISTER PACK in 1 CARTON (67184-0531-3) / 10 TABLET, COAT...	Gefitinib	Qilu Pharmaceutical Co., Ltd.	2023-02-13
69339-0168-03	30 TABLET, FILM COATED in 1 BOTTLE (69339-168-03)	Gefitinib	Natco Pharma USA LLC	2023-06-05

Observed labelers: Qilu Pharmaceutical Co., Ltd. (3) · AstraZeneca Pharmaceuticals LP (1) · Ingenus Pharmaceuticals, LLC (1) · Natco Pharma USA LLC (1) · Teva Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.